Table 5.
Comparisons low GDP PD patients with and without history of peritonitis, who were on PD for at least 24 months.
| No peritonitis | Previous peritonitis | p-value | |
|---|---|---|---|
| Tissue samples (n) | 14 | 16 | |
| Age (years) | 7.4 (4.4, 16.7) | 13.2 (6.7, 18.0) | 0.35 |
| Gender (% female) | 42% | 38% | 0.82 |
| BSA (m2) | 0.7 (0.6, 1.3) | 1.0 (0.8, 1.3) | 0.20 |
| PD duration (months)∗ | 37.6 (30.3, 48.0) | 52.0 (32.9, 73.0) | 0.30 |
| Glucose exposure (g/m2/day) | 124.4 (64.3, 216.2) | 119.8 (111.9, 146.2) | 0.82 |
| Mesothel absent | 50% | 76% | 0.32 |
| Mesothel score (0–6) | 0 (0, 2) | 0 (0, 1.5) | 0.42 |
| Submesothelial thickness (μm) | 314 (223.3, 511.0) | 527 (308.5, 844.0) | 0.058 |
| Microvessel density (/mm2) | 157.4 (97.9, 278.7) | 192.4 (149.7, 236.6) | 0.96 |
| Submesothelial microvessel number (/mm) | 43.4 (26.0, 66.5) | 85.9 (53.1, 179.4) | 0.014 |
| Lymphatic vessel density (/mm2) | 53.5 (14.5, 59.0) | 25.1 (14.9, 39.5) | 0.41 |
| Diffuse podplanin staining | 25% | 41% | 0.37 |
| Blood cap. vessel density (/mm2) | 96 (65, 204) | 189 (126, 224) | 0.57 |
| Total endothelial surface area (μm2/μm3) | 8.2 (5.5, 15.2) | 9.7 (8.5, 11.5) | 0.93 |
| Lym. endothelial surface area (μm2/μm3) | 4.1 (1.1, 5.8) | 1.7 (0.9, 2.5) | 0.14 |
| Blood cap. end. surface area (μm2/μm3) | 7.3 (2.3, 9.0) | 7.5 (6.8, 10.9) | 0.62 |
| L/V ratio | 0.5 (0.2, 0.5) | 0.4 (0.2, 0.5) | 0.52 |
| ASMA positivity (%) | 33% | 71% | 0.017 |
| ASMA score (0–3) | 0.0 (0.0, 1.5) | 2.0 (0.0, 3.0) | 0.56 |
| CD45 positivty (%) | 50% | 76% | 0.23 |
| CD45 score (0–3) | 0.5 (0.0, 1.0) | 1.0 (1.0, 2.0) | 0.79 |
| CD68 positivity (%) | 67% | 76% | 0.73 |
| CD68 score (0–3) | 1.0 (0.0, 1.0) | 1.0 (1.0, 2.0) | 0.14 |
| Fibrine positivity (%) | 8% | 18% | 0.47 |
| EMT presence | 25% | 53% | 0.13 |
| EMT (cells/mm2)∗∗ | 20.0 (5.0, 20.0) | 11.3 (3.0, 26.6) | 0.92 |
| VEGF (% submes. area) | 46.6 (16, 49.7) | 28.7 (22.2, 42.9) | 0.44 |
| pSMAD (% submes. area) | 11.7 (9.2, 18.2) | 25.8 (8.5, 33.6) | 0.11 |
Cap., capillary; end., endothelial; lym., lymphatic; submes., submesothelial. L/V ratio, lumen diameter/vessel ratio; ASMA, alpha smooth muscle actin; EMT, epithelial to mesenchymal transition. VEGF, vascular endothelial growth factor. ∗At time of biopsy. ∗∗Only cell scores from EMT positive patients included.